Research programme: anti-bacterial lysin therapies - Lysigen
Latest Information Update: 20 Feb 2024
At a glance
- Originator Lysigen
- Class Antibacterials; Endolysins; Recombinant proteins
- Mechanism of Action Peptidoglycan degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections; Gram-positive infections
Most Recent Events
- 25 Jan 2024 Early research in Bacterial infections in USA (unspecified route) (Lysigen Pipeline, Prior to January 2024)
- 25 Jan 2024 Early research in Gram-positive infections in USA (unspecified route) (Lysigen Pipeline, Prior to January 2024)